email article
With a vulnerable population, centralized care, and a strong system in place for other shots, dialysis providers argue that they should be part of the early rollout with higher prioritization for their patients. I have talked to dialysis providers large and small across the country, and it is a unanimous opinion that we would like to be able to vaccinate our patients, in our facilities, by our staff, said Jeffrey Silberzweig, MD, co-chair of the American Society of Nephrology (ASN) COVID-19 Response Team.
End-stage renal disease (ESRD) patients are among the most vulnerable populations for poor outcomes of COVID-19. They had the highest rate of COVID-19 hospitalization among all Medicare beneficiaries four-fold that of other age-matched seniors; their COVID-19 mortality rate was 25-fold that of other Medicare beneficiaries the same age.
Access denied
Racial minorities in America are much more vaccine hesitant
That need not be such a hurdle to getting Americans vaccinated once their access to the vaccine improves
T
HE BIDEN administration has pledged to deliver 150m covid-19 vaccinations within the president’s first 100 days in office, but who should get those shots? Most states are prioritising frontline health-care workers and long-term care-home residents, followed by people aged 75 or older and essential workers. Few states are making sure African-Americans or Hispanics get vaccinated, even though they are three times more likely to die from the virus than whites. In fact minorities may be at the back of the queue for something that is of great value to all Americans.
National Institute of Allergy and Infectious Diseases, NIH
A press release from a Canadian research group raised hopes that treating people recently diagnosed with Covid-19 with colchicine, a drug commonly used to treat gout, could reduce the risk they will need to be hospitalized.
But outside experts said the data provided were too limited to draw conclusions, leading to discussions of the risks of conducting science via press release, instead of in more detailed manuscripts in peer-reviewed journals. All hoped that colchicine, a cheap and globally available generic medicine with manageable side effects, would prove to be beneficial.
“I’m not, ‘Oh, I don’t buy it’,” said Ashish Jha, dean of the Brown University School of Public Health. “It’s possible. There’s enough plausibility here. This could be a real finding, and if it is that would be great. But this press release doesn’t get us there.”
Immune system s malfunctioning may trigger Parkinson s, says study
Immune system s malfunctioning may trigger Parkinson s, says study
The First Direct Evidence That Parkinson s Disease Is Partly An Autoimmune Disorder In Which The Tissues Are Attacked By The Body s Immune System, Found The Researchers.
News Nation Bureau | Edited By : Navnidhi Chugh | Updated on: 22 Jun 2017, 07:22:43 PM
New Delhi:
The first direct evidence that Parkinson s disease is partly an autoimmune disorder in which the tissues are attacked by the body s immune system, found the researchers.
According to the findings, the death of the neurons in Parkinson s could be prevented by therapies that moisten the immune response.